Project Grant HT94252310865
- This federal Project Grant award for $1,679,104 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by St. Jude Children's Research Hospital Inc. to investigate pre-mRNA splicing as a potential therapeutic vulnerability for pediatric liver cancer. The award, with a performance period from September 30, 2025 to September 29, 2028, will fund sophisticated scientific research, including the development of novel...
- The U.S. Defense Health Agency awarded a $1,036,000 Project Grant to St. Jude Children's Research Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) to support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The grant, which runs from November 1, 2025 to October 31, 2029, will fund research to identify NEK5 as a hidden driver in kidney cancer. As a renowned nonprofit pediatric...
- This $980,501 Project Grant was awarded on June 15, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to St. Jude Children's Research Hospital Inc. The grant supports advanced biomedical research focused on "CELL INTRINSIC AND EXTRINSIC MODIFIERS OF BMF PROGRESSION IN SAMD9L SYNDROMES" with a performance period from June 15, 2025 to June 14, 2028. As a renowned pediatric treatment and research institution, St. Jude Children's...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,295,000.00 to St. Jude Children's Research Hospital Inc. to conduct research aimed at creating cures for patients with Langerhans cell histiocytosis. The award period runs from September 1, 2024 to August 31, 2028. This research project builds upon St. Jude's extensive experience in pediatric cancer and other life-threatening diseases in...
- This Project Grant award of $728,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by St. Jude Children's Research Hospital Inc. on XPO1 as a therapeutic target in ZFTA-RELA-driven ependymoma. The two-year award, running from September 1, 2023 to August 31, 2025, will fund medical research to investigate XPO1 as a potential treatment for this rare pediatric brain cancer. The research focuses on...
- This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
- The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $591,248 Project Grant to St. Jude Children's Research Hospital Inc. to conduct research on "SMARCAL1: A UNIQUE TARGET IN ALT-POSITIVE PEDIATRIC SOLID TUMORS." The project will run from September 30, 2024 to September 29, 2026. As part of this grant, St. Jude Children's Research Hospital Inc. will be collaborating with Icahn School of Medicine at Mount Sinai as a...
- The Defense Health Agency awarded a $1,528,727.00 Project Grant to Children's Research Institute, a subsidiary of Children's National Medical Center, to develop SGT-53, a novel nanomedicine that crosses the blood-brain barrier and augments immunotherapeutic response in pediatric brain cancers. This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for Service Members and the...
- The Department of Defense, through its Military Medical Research and Development program (CFDA 12.420), awarded a $624,000 project grant to the Research Institute at Nationwide Children's Hospital in Columbus, Ohio. The 2-year grant, which began on September 1, 2025, will support comprehensive in vivo phenotyping research on fusion-driven pediatric rhabdomyosarcomas. The Research Institute, a leading pediatric research organization, will leverage its expertise in advanced biomedical research and...
- This $564,705 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Duke University to identify essential drug targets for common and rare oncofusions in rhabdomyosarcoma, a type of cancer. The 3-year project, with a performance period from September 2025 to September 2028, aims to advance the understanding of oncofusion-interacting proteins and their potential as therapeutic targets for this...
This Project Grant award for $1,340,665.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to St. Jude Children's Research Hospital Inc. The award supports research focused on the FGFR pathway as a lead therapeutic vulnerability in pediatric ependymoma, a type of brain cancer in children. The project will be conducted over 3 years, from September 1, 2023 to August 31, 2026, and aims to advance the development of effective treatments for this devastating pediatric disease. As a leading pediatric cancer research institution, St. Jude Children's Research Hospital Inc. has significant expertise in this area and has received prior federal funding for related oncology research projects.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.3m | 8/7/23 |